Drug Exposure to Establish Pharmacokinetic–Response Relationships in Oncology Belén P. SolansMaría Jesús GarridoIñaki F. Trocóniz Review Article 26 October 2019 Pages: 123 - 135
Clinical Pharmacokinetics and Pharmacodynamics of Etravirine: An Updated Review Joshua P. HavensAnthony T. PodanyCourtney V. Fletcher Review Article 02 November 2019 Pages: 137 - 154
Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences Hanne HaahrTim Heise Review Article Open access 30 October 2019 Pages: 155 - 172
Pharmacokinetics and Target Attainment of Antibiotics in Critically Ill Children: A Systematic Review of Current Literature Stan J. F. HartmanRoger J. BrüggemannSaskia N. de Wildt Systematic Review Open access 20 August 2019 Pages: 173 - 205
A Semi-Mechanistic Population Pharmacokinetic/Pharmacodynamic Model of Bortezomib in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia Julie M. JanssenT. P. C. DorloA. D. R. Huitema Original Research Article 16 July 2019 Pages: 207 - 216
Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies Ken OgasawaraKathryn NewhallYan Li Original Research Article Open access 22 July 2019 Pages: 217 - 227
Population Pharmacokinetics of Apalutamide and its Active Metabolite N-Desmethyl-Apalutamide in Healthy and Castration-Resistant Prostate Cancer Subjects Carlos Pérez-RuixoJonás Samuel Pérez-BlancoOliver Ackaert Original Research Article 20 August 2019 Pages: 229 - 244
Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup Pierre ChelleCindy H. T. YeungAlfonso Iorio Original Research Article 22 August 2019 Pages: 245 - 256
Population Pharmacokinetics of Intravenous Salbutamol in Children with Refractory Status Asthmaticus Nienke J. VetBrenda C. M. de WinterMatthijs de Hoog Original Research Article Open access 21 August 2019 Pages: 257 - 264
Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?” Axel Krebs-BrownAlain MunafoClaire Castello-Bridoux Letter to the Editor Open access 05 December 2019 Pages: 265 - 267
Authors’ Reply to Krebs-Brown et al. Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?” D. ConcordetP. GandiaP. L. Toutain Letter to the Editor Open access 05 December 2019 Pages: 269 - 271
Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?” Patrick Nicolas Letter to the Editor 05 December 2019 Pages: 273 - 275
Authors’ Reply to Nicolas: “Why Were More than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?” Didier ConcordetPeggy GandiaPierre-Louis Toutain Letter to the Editor Open access 05 December 2019 Pages: 277 - 279
Comment on “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?” Yang YuMarc Maliepaard Letter to the Editor 05 December 2019 Pages: 281 - 282
Authors’ Reply to Yu et al.: “Levothyrox® New and Old Formulations: Are They Switchable for Millions of Patients?” Didier ConcordetPeggy GandiaPierre-Louis Toutain Letter to the Editor Open access 05 December 2019 Pages: 283 - 285